000283130 001__ 283130
000283130 005__ 20240229155048.0
000283130 0247_ $$2doi$$a10.1097/HJH.0000000000003579
000283130 0247_ $$2pmid$$apmid:37732518
000283130 0247_ $$2ISSN$$a0263-6352
000283130 0247_ $$2ISSN$$a1473-5598
000283130 037__ $$aDKFZ-2023-01917
000283130 041__ $$aEnglish
000283130 082__ $$a610
000283130 1001_ $$aSchott, Artjom$$b0
000283130 245__ $$aAssociation of subendocardial viability ratio and mortality in the elderly population: results from the CARdiovascular disease, Living and Ageing in Halle study.
000283130 260__ $$aLondon$$bLippincott, Williams & Wilkins$$c2024
000283130 3367_ $$2DRIVER$$aarticle
000283130 3367_ $$2DataCite$$aOutput Types/Journal article
000283130 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704441038_4929
000283130 3367_ $$2BibTeX$$aARTICLE
000283130 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283130 3367_ $$00$$2EndNote$$aJournal Article
000283130 500__ $$a2024 Feb 1;42(2):371-376
000283130 520__ $$aThe subendocardial viability ratio (SEVR) reflects the balance of myocardial oxygen supply and demand. Low SEVR indicates a reduced subendocardial perfusion and has been shown to predict mortality in patients with kidney disease and diabetes. The aim of this study is to investigate the association of SEVR and mortality in the elderly population.We analysed data from the CARdiovascular disease, Living and Ageing in Halle (CARLA) study. SEVR was estimated noninvasively by radial artery tonometry and brachial blood pressure measurement. The study population was divided into a low (SEVR ≤130%) and normal (SEVR >130%) SEVR group. Cox-regression was used for survival analysis.In total, 1414 participants (635 women, 779 men) aged from 50 to 87 years (mean age 67.3 years) were included in the analysis. The all-cause mortality was 22.7% during a median follow-up of 10.5 years. The unadjusted association of SEVR with all-cause mortality decreased from 3.52 (1.31-9.46) [hazard ratio (95% confidence interval) for low SEVR ≤ 130% versus normal SEVR > 130%] among those younger than 60 years to 0.86 (0.50-1.48) among those older than 80 years and from 1.81 (0.22-14.70) to 0.75 (0.30-1.91) for cardiovascular mortality. Sex-specific unadjusted analyses demonstrated an association of SEVR with all-cause and cardiovascular mortality in men [2.32 (1.61-3.34) and 2.24 (1.18-4.24)], but not in women [1.53 (0.87-2.72) and 1.14 (0.34-3.82)].Our data suggests that SEVR is an age dependent predictor for all-cause mortality, predominantly in men younger than 60 years.
000283130 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000283130 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000283130 7001_ $$aKluttig, Alexander$$b1
000283130 7001_ $$aMikolajczyk, Rafael$$b2
000283130 7001_ $$aGroßkopf, Anne$$b3
000283130 7001_ $$0P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aGreiser, Karin Halina$$b4$$udkfz
000283130 7001_ $$aWerdan, Karl$$b5
000283130 7001_ $$aSedding, Daniel$$b6
000283130 7001_ $$aNuding, Sebastian$$b7
000283130 773__ $$0PERI:(DE-600)2017684-3$$a10.1097/HJH.0000000000003579$$n2$$p371-376$$tJournal of hypertension$$v42$$x0263-6352$$y2024
000283130 909CO $$ooai:inrepo02.dkfz.de:283130$$pVDB
000283130 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000283130 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000283130 9141_ $$y2023
000283130 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000283130 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000283130 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000283130 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-22$$wger
000283130 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ HYPERTENS : 2022$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000283130 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000283130 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000283130 980__ $$ajournal
000283130 980__ $$aVDB
000283130 980__ $$aI:(DE-He78)C020-20160331
000283130 980__ $$aUNRESTRICTED